-+ 0.00%
-+ 0.00%
-+ 0.00%
AstraZeneca: BREZTRI is now available in the US, making it the first and only fixed-dose triple therapy for asthma patients aged 12 and above.
Share
Listen to the news
AstraZeneca: BREZTRI is now available in the US, making it the first and only fixed-dose triple therapy for asthma patients aged 12 and above.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending